Schizophrenia News and Research

Latest Schizophrenia News and Research

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

Intellectual disability may have genetic origin, but is not hereditary

Mutations in a group of genes associated with brain activity frequently cause intellectual disability, according to a study led by scientists affiliated with the University of Montreal and the research centre at the Centre hospitalier universitaire Sainte-Justine. Intellectual disability is a severe handicap that affects between one and two percent of children worldwide. It can often be attributed to genetic causes, but the specific genes involved were mostly unknown.

18 Apr 2011

Patients with schizophrenia can benefit from L-lysine treatment

Schizophrenia is a serious mental disorder that currently affects about one in every 200 people. Most patients find some relief from their symptoms by treatment with antipsychotics, however they may still suffer from cognitive and negative symptoms.

18 Apr 2011

Scientists identify filter neurons that can reduce 'brain clutter'

Until now, it has been assumed that people with diseases like ADHD, Tourette syndrome, obsessive compulsive disorder and schizophrenia - all of whom characteristically report symptoms of "brain clutter" - may suffer from anomalies in the brain's prefrontal cortex.

15 Apr 2011

Vanda initiates Fanapt Phase I study in patients with schizophrenia

Vanda Pharmaceuticals Inc. announced today that Novartis Pharmaceuticals Corporation, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable formulation of Fanapt.

11 Apr 2011

Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR

Targacept, Inc. today announced the presentation of data from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia at the International Congress on Schizophrenia Research in Colorado Springs, Colorado.

8 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011

Molecular switch regulating protein behavior increases human susceptibility to schizophrenia, mood disorders

Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.

7 Apr 2011

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Neurocrine Biosciences, Inc. announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

6 Apr 2011

Scientists reveal metabolic abnormalities underlying schizophrenia

Scientists in Finland have revealed metabolic abnormalities that are associated with schizophrenia. This may be an important step towards development of a clinical test of the disease.

5 Apr 2011

National Alliance for Research on Schizophrenia and Depression is now Brain & Behavior Research Foundation

The Brain & Behavior Research Foundation (formerly NARSAD, the National Alliance for Research on Schizophrenia and Depression) continues its 25-year mission to alleviate the suffering of mental illness by awarding grants that will lead to advances and breakthroughs in scientific research.

5 Apr 2011

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry shows treatment with Risperdal Consta is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

5 Apr 2011

Researchers develop new way to stimulate neuron production in adult brain

Researchers at Columbia University Medical Center have developed a new way to stimulate neuron production in the adult mouse brain, demonstrating that neurons acquired in the brain's hippocampus during adulthood improve certain cognitive functions.

4 Apr 2011

ACADIA extends collaboration agreement with Allergan for drug discovery platform

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc.

1 Apr 2011

NAMI launches new schizophrenia website and brochure

The National Alliance on Mental Illness has launched a new website on schizophrenia and published a new brochure on the medical condition which affects more than 2.4 million American adults each year.

1 Apr 2011

New schizophrenia research reveals difference in identical twins genetic makeup

Just like snowflakes, no two people are alike, even if they're identical twins according to new genetic research from The University of Western Ontario. Molecular geneticist Shiva Singh has been working with psychiatrist Dr. Richard O'Reilly to determine the genetic sequencing of schizophrenia using identical or monozygotic twins. The study is published in this month's PLoS ONE.

29 Mar 2011

XTL announces MinoGuard acquisition

XTL announced on March 24, 2011, it entered into a term sheet to acquire the activity of MinoGuard Ltd. by obtaining an exclusive license to use MinoGuard's entire technology in return for royalties on sales and milestone payments throughout the clinical development process.

25 Mar 2011

AssureRx closes $11 million Series B financing

AssureRx Health, Inc. today announced the closing of an $11 million Series B financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug and the right dose for individual neuropsychiatric patients, will use the funds to expand direct sales and marketing for its first product, GeneSightRx®, and for second generation product development activities.

25 Mar 2011

Study finds eye movement difference in two different populations

The team, working with Sichuan University in Chengdu, China, investigated eye movements in Chinese and British people to further understanding of the brain mechanisms that control them and how they compare between different human populations.

25 Mar 2011

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.

25 Mar 2011